title: Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals.
abstract: Dendritic cells (DC) have an instrumental role in the activation and function of both innate and adaptive immune responses. In humans, at least two distinct DC subsets have been characterized based on phenotypic markers: the myeloid DC (MDC) and the plasmacytoid DC (PDC). Both subsets are critical producers of cytokines (IL-12 for MDC and type I/II IFNs for PDC) and are functionally different. We show in this study that HIV(+) individuals have a significant decrease in the number of the Lin(-)HLA-DR(+)CD123(+) and BDCA-2(+) PDC compared with uninfected donors (p = 0.0001). HIV(+) individuals also have a sustained impairment in viral-induced IFN-alpha production (p < 0.0001). The decrease of the PDC subsets did not correlate with CD4 count or viral load and was not reversed in subjects under virally suppressive treatment, suggesting an irreversible change after infection. By contrast, the absolute number and median frequency of MDC in HIV-infected individuals were similar to those observed in uninfected controls, while a significant decrease was present in subjects with >5000 HIV-1 copies/ml. The inverse association with viral load of the MDC number, but not of IFN-alpha secretion or the number of PDC, suggests a role for MDC in viral control. Our data suggest that DC subsets are differentially reconstituted during the immune recovery associated with antiviral therapy. The persistent impairment of certain DC subsets may result in a sustained defect in DC-mediated innate immune functions despite an effective treatment regimen.
authors.affiliation: HIV Immunopathogenesis Laboratory, Wistar Institute, Philadelphia, PA 19104, USA.
authors.forename: Jihed
authors.initials: J
authors.lastname: Chehimi
authors.forename: Donald E
authors.initials: DE
authors.lastname: Campbell
authors.forename: Livio
authors.initials: L
authors.lastname: Azzoni
authors.forename: Darlene
authors.initials: D
authors.lastname: Bacheller
authors.forename: Emmanouil
authors.initials: E
authors.lastname: Papasavvas
authors.forename: Ghassen
authors.initials: G
authors.lastname: Jerandi
authors.forename: Karam
authors.initials: K
authors.lastname: Mounzer
authors.forename: Jay
authors.initials: J
authors.lastname: Kostman
authors.forename: Giorgio
authors.initials: G
authors.lastname: Trinchieri
authors.forename: Luis J
authors.initials: LJ
authors.lastname: Montaner
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D001772:Blood Cell Count; D018791:CD4 Lymphocyte Count; D002452:Cell Count; D002478:Cells, Cultured; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003713:Dendritic Cells / Q000145:classification / Q000276:immunology*; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000096:biosynthesis; D053650:Interleukin-3 Receptor alpha Subunit; D037102:Lectins / Q000032:analysis; D037181:Lectins, C-Type; D007959:Lymphocyte Culture Test, Mixed; D008562:Membrane Glycoproteins; D022423:Myeloid Cells / Q000276:immunology; D011971:Receptors, Immunologic; D016185:Receptors, Interleukin-3 / Q000032:analysis; D019562:Viral Load
chemical_list: C443299:CLEC4C protein, human; C115022:IL3RA protein, human; D053650:Interleukin-3 Receptor alpha Subunit; D037102:Lectins; D037181:Lectins, C-Type; D008562:Membrane Glycoproteins; D011971:Receptors, Immunologic; D016185:Receptors, Interleukin-3; D007371:Interferon-gamma